{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T15:28:53Z","timestamp":1726759733744},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.ejca.2012.11.006","type":"journal-article","created":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T22:46:03Z","timestamp":1362696363000},"page":"1205-1215","source":"Crossref","is-referenced-by-count":15,"title":["Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer"],"prefix":"10.1016","volume":"49","author":[{"given":"Erzs\u00e9bet","family":"Juh\u00e1sz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo-Hang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u00eblle","family":"Klingelschmitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Walzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2012.11.006_b0005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/annonc\/mdl498","article-title":"Estimates of the cancer incidence and mortality in Europe in 2006","volume":"18","author":"Ferlay","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2012.11.006_b0010","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/(SICI)1098-2388(200003)18:2<106::AID-SSU4>3.0.CO;2-P","article-title":"The international system for staging lung cancer","volume":"18","author":"Mountain","year":"2000","journal-title":"Semin Surg Oncol"},{"key":"10.1016\/j.ejca.2012.11.006_b0015","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/bjc.1993.306","article-title":"The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival","volume":"68","author":"Veale","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2012.11.006_b0020","first-page":"515","article-title":"Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression","volume":"3","author":"Rusch","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2012.11.006_b0025","first-page":"241","article-title":"Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I\u2013IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival","volume":"4","author":"Fontanini","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2012.11.006_b0030","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/annonc\/mdh011","article-title":"Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer","volume":"15","author":"Selvaggi","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2012.11.006_b0035","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1200\/JCO.2003.11.069","article-title":"Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis","volume":"21","author":"Hirsch","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.11.006_b0040","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/sj.bjc.6602149","article-title":"Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer","volume":"91","author":"Swinson","year":"2004","journal-title":"Br J Cancer"},{"issue":"Suppl. 4","key":"10.1016\/j.ejca.2012.11.006_b0045","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0959-8049(01)00231-3","article-title":"EGFR and cancer prognosis","volume":"37","author":"Nicholson","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2012.11.006_b0050","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11864-007-0020-6","article-title":"Optimal duration of chemotherapy in advanced non-small cell lung cancer","volume":"8","author":"Lustberg","year":"2007","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ejca.2012.11.006_b0055","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/JCO.2004.09.053","article-title":"American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003","volume":"22","author":"Pfister","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.11.006_b0060","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL","volume":"27","author":"Reck","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.11.006_b0065","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel\u2013carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2012.11.006_b0070","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1097\/JTO.0b013e3181da36f4","article-title":"Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel\/carboplatin for advanced non-small cell lung cancer","volume":"5","author":"Sandler","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2012.11.006_b0075","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1634\/theoncologist.2008-0152","article-title":"Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line?","volume":"14","author":"Gridelli","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2012.11.006_b0080","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1634\/theoncologist.12-4-451","article-title":"Sequential, alternating, and maintenance\/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature","volume":"12","author":"Grossi","year":"2007","journal-title":"Oncologist"},{"issue":"Suppl. 2","key":"10.1016\/j.ejca.2012.11.006_b0195","doi-asserted-by":"crossref","first-page":"ii67","DOI":"10.1093\/annonc\/mdj928","article-title":"Maintenance chemotherapy in non-small cell lung cancer","volume":"17","author":"Rinaldi","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2012.11.006_b0090","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1517\/14740338.2011.540799","article-title":"Reviewing the safety of erlotinib in non-small cell lung cancer","volume":"10","author":"Reck","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ejca.2012.11.006_b0095","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human use post-authorisation summary of positive opinion for Tarceva. http:\/\/www.emea.europa.eu\/pdfs\/human\/opinion\/51116606en.pdf."},{"key":"10.1016\/j.ejca.2012.11.006_b0100","unstructured":"US Food and Drug Administration. Tarceva. Label and approval history. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.DrugDetails. [Accessed 22 October 2010]."},{"key":"10.1016\/j.ejca.2012.11.006_b0200","first-page":"753s","article-title":"The impact of ECOG performance status on quality of life symptoms in patients with advanced lung cancer","volume":"23","author":"Hensing","year":"2005","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.ejca.2012.11.006_b0110","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","article-title":"Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study","volume":"11","author":"Cappuzzo","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2012.11.006_b0115","unstructured":"Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System. Version 4. Evanston, IL: Center on Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare and Northwestern University; 1997."},{"key":"10.1016\/j.ejca.2012.11.006_b0120","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0895-4356(01)00477-2","article-title":"What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592","volume":"55","author":"Cella","year":"2002","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejca.2012.11.006_b0125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1023\/A:1015276414526","article-title":"Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening","volume":"11","author":"Cella","year":"2002","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ejca.2012.11.006_b0130","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1023\/B:QURE.0000021703.47079.46","article-title":"Interpreting differences in quality of life: the FACT-H&N in laryngeal cancer patients","volume":"13","author":"Ringash","year":"2004","journal-title":"Qual Life Res"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2012.11.006_b0205","first-page":"S83","article-title":"Erlotinib as third-line therapy in advanced\/metastatic non small cell lung cancer (NSCLC): results from a single-centre experience","volume":"3","author":"Rozzi","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2012.11.006_b0210","first-page":"695s","article-title":"Improvement in symptoms and quality of life (QoL) for patients (p) with non-small cell lung cancer (NSCLC) treated with erloninib: TargeT study","volume":"25","author":"Alberola","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.ejca.2012.11.006_b0145","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0169-5002(95)00450-F","article-title":"Reliability and validity of the functional assessment of cancer therapy \u2013 lung (FACT-L) quality of life instrument","volume":"12","author":"Cella","year":"1995","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2012.11.006_b0150","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(09)61497-5","article-title":"Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study","volume":"374","author":"Ciuleanu","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2012.11.006_b0155","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2008.17.1405","article-title":"Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer","volume":"27","author":"Fidias","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.11.006_b0215","first-page":"28","article-title":"A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01\/03)","author":"Gaafar","year":"2010","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.ejca.2012.11.006_b0220","first-page":"28","author":"Kabbinavar","year":"2010","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.ejca.2012.11.006_b0225","first-page":"28","article-title":"Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT\u2013GFPC 0502 phase III study","author":"Perol","year":"2010","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.ejca.2012.11.006_b0175","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human use post-authorisation summary of positive opinion for Alimta. http:\/\/www.emea.europa.eu\/pdfs\/human\/opinion\/Alimta_9292908en.pdf."},{"key":"10.1016\/j.ejca.2012.11.006_b0180","doi-asserted-by":"crossref","unstructured":"Casciano R, Bischoff H, Nuijten M, Malangone E, Ray J. Maintenance erlotinib versus pemetrexed for the treatment of non-small cell lung cancer: Indirect comparison applying real-life outcomes. Presented at the ISPOR 13th Annual European Congress, Prague, Czech Republic, 6\u20139 November 2010.","DOI":"10.1016\/S1098-3015(11)71917-9"},{"key":"10.1016\/j.ejca.2012.11.006_b0185","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","article-title":"TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.11.006_b0190","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.2005.05.1474","article-title":"Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation trial","volume":"25","author":"Gatzemeier","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804912008908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804912008908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T12:44:58Z","timestamp":1562762698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804912008908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0959804912008908"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2012.11.006","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}